7:01 am ET on Tuesday

For Immediate Release - 7:01 am ET on

Tuesday, March 18, 2025

Acurx Pharmaceuticals,

Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Staten Island, NY, March 18, 2025 -

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company

developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results

for the fourth quarter and full year ended December 31, 2024.

Highlights of the fourth quarter ended December

31, 2024, or in some cases shortly thereafter, include:

According to Dr. Garey: "These exciting

results demonstrate two properties of ibezapolstat which may contribute to its anti-recurrence effect. First, the preservation and restoration

of beneficial bacterial classes in the gut provide resistance to recolonization by C. difficile. Second, these data, presented for the

first time, indicate that these beneficial bacteria known to metabolize primary to secondary bile acids persist in ibezapolstat-treated

patients providing another important mechanism to prevent recurrent CDI"

This study is the first ever head-to-head

comparison of gut microbiome changes associated with IBZ when compared to other anti-CDI antibiotics in a germ-free mouse model.

The data showed that changes in alpha and

beta microbiome diversities following IBZ treatment were less pronounced compared to those observed in vancomycin (VAN)-or metronidazole

(MET)-treated groups, complementing prior Phase 2 clinical findings showing IBZ's more selective antibacterial activity.

Further, and very importantly, notable

differences were observed between the microbiome of IBZ- and the fidaxomicin (FDX)-treated groups, which may allow for differentiation

of these two anti-CDI antibiotics in future studies.

These results establish IBZ's differentiating

effects on the gut microbiome, indicating a more selective spectrum of microbiome alteration compared to broader-spectrum antibiotics

like VAN and MET and a narrower spectrum of microbiome alteration compared to FDX.

Fourth Quarter and Full Year 2024 Financial

The Company ended the year with cash totaling

$3.7 million, compared to $7.5 million as of December 31, 2023. The Company raised a total of $6.6 million of gross proceeds under its

ATM financing program for the year ended December 31, 2024.

Research and development expenses for the

three months ended December 31, 2024 were $0.8 million compared to $1.9 million for the three months ended December 31, 2023, a decrease

of $1.1 million. The decrease was due primarily to a decrease in consulting related costs of $1.2 million, offset by an increase in manufacturing

costs of $0.1 million. For the year ended December 31, 2024 research & development expenses were $5.4 million compared to $6.0 million

for the year ended December 31, 2023, a decrease of $0.6 million. The decrease was primarily due to a $1.6 million decrease in consulting

related costs, offset by a $1.0 million increase in manufacturing related costs.

General and administrative expenses for

the three months ended December 31, 2024 were $2.0 million compared to $3.2 million for the three months ended December 31, 2023, a decrease

of $1.2 million. The decrease was primarily due to $0.5 million decrease in professional fees, a $0.5 million decrease in share-based

compensation costs, and a $0.2 million decrease in employee compensation costs. For the year ended December 31, 2024, general and administrative

expenses were $8.7 million compared to $8.5 million for the year ended December 31, 2023, an increase of $0.2 million. The increase was

primarily due to $0.7 million increase in professional fees, a $0.3 million increase in legal fees, offset by a $0.6 million decrease

in share-based compensation costs and a $0.2 million decrease in insurance costs.

The Company reported a net loss of $2.8

million or $0.16 per diluted share for the three months ended December 31, 2024 compared to a net loss of $5.1 million or $0.37 per diluted

share for the three months ended December 31, 2023, and a net loss of $14.1 million or $0.87 per share for the year ended December 31,

2024, compared to a net loss of $14.6 million or $1.15 per share for the year ended December 31, 2023 for the reasons previously mentioned.

The Company had 17,030,686 shares outstanding as

of December 31, 2024.

As previously announced, David P. Luci, President

and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide

a business update as follows:

Ibezapolstat is the Company's lead antibiotic

candidate advancing to international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI). Ibezapolstat

is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS ) antibacterial.

It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's

unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria phyla, appears

to contribute to the maintenance of a healthy gut microbiome. In June 2018, ibezapolstat was designated by the U.S. Food and Drug Administration

(FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI and will be eligible to benefit from the

incentives for the development of new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In January

2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The CDC has designated C.

difficile as an urgent threat highlighting the need for new antibiotics to treat CDI.

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals is a late-stage biopharmaceutical

company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach

is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS ) that blocks the active site of the Gram-positive

specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death.

Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-

resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B.

anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Acurx's lead product candidate, ibezapolstat, for the treatment

of C. difficile Infection is Phase 3 ready with plans in progress to begin international clinical trials next year. The Company's preclinical

pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections),

upon which a development program for treatment of inhaled anthrax is being planned in parallel.

To learn more about Acurx Pharmaceuticals and

its product pipeline, please visit www.acurxpharma.com.

Forward-Looking Statements

Any statements in this press release about our

future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives,

and other statements containing the words "believes," "anticipates," "plans," "expects," and similar

expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual

results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including:

whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a

timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval,

and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought;

whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described

in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended

December 31, 2024, and in the Company's subsequent

filings with the Securities and Exchange

Commission. Such forward- looking statements speak

only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to

reflect events or circumstances after the date of such statements, except as may be required by law.

Acurx Pharmaceuticals, Inc.

David P. Luci, President & Chief Executive

Email: davidluci@acurxpharma.com

Source: Acurx Pharmaceuticals, Inc.

ACURX PHARMACEUTICALS, INC.

AS OF DECEMBER 31, 2024 and 2023

ACURX PHARMACEUTICALS, INC.